This invention is in the field of molecular biology, gene expression, functional genomics, and bioinformatics and relates to novel RNA and related structures and methods of use thereof that enables modulation of gene expression and preservation of particular transcriptome targets. The invention contemplates various applications of RNA sequences derived from the genomic RNA of flaviviruses (FVs) and the application of such features in combination with heterologous sequences.

The present invention relates to processes for producing compositions comprising (i) a virus-like particle of an RNA bacteriophage, and (ii) aggregated oligonucleotides, wherein said aggregated oligonucleotides are packaged into said virus-like particle. The invention further provides processes for producing nucleotide compositions comprising aggregated oligonucleotides suitable for use in the aforementioned processes before. Moreover, the invention further provides nucleotide compositions comprising aggregated oligonucleotides. Furthermore, the invention further provides compositions comprising (i) a virus-like particle of an RNA bacteriophage, and (ii) aggregated oligonucleotides, wherein said aggregated oligonucleotides are packaged into said virus-like particle.

In some embodiments, complex molecular knots with high crossing numbers are achieved by folding, following a prescribed folding order, single-stranded DNA or RNA of customized sequences into target shapes. Such complex molecular knots with high crossing numbers are useful for biomedical applications including use as immunostimulatory agents and/or protein hosts and carriers.

The present disclosure provides donor polynucleotides, genome editing systems, methods, and kits which correct or induce a mutation in a gDNA.

The present disclosure provides polynucleotide-based inhibitors for reversible activation of DNA polymerases. Use of lower Tm polynucleotide-based inhibitors allow PCR reaction assembly at room temperature while activating polymerase at higher PCR primer annealing temperatures, where the reversible nature of the inhibition additionally improves priming specificity during each PCR cycle. Additionally, temperature controlled inactivation of polymerase activity after PCR or other polymerase based enzymatic incubation eliminates a purification step when needed for compatibility with subsequent enzymatic incubations. For this application, the T.sub.m of the polynucleotide-based inhibitor is higher than the desired reaction conditions of the subsequent enzymatic incubation.

Systems and method for providing chaperone activity to a protein-containing compound is disclosed. The method includes selecting a nucleic acid based on one or more of the nucleic acid's particular properties and a specific sequence of the nucleic acid and applying the nucleic acid to a compound comprising one or more proteins to provide chaperone activity to the compound.

Methods for capturing a target nucleic acid from a sample by using a capture probe that binds nonspecifically to the target nucleic acid and binds specifically to an immobilized probe via a specific binding pair that has one member on the capture probe and one member on the immobilized probe are disclosed. Compositions that include a capture probe that binds nonspecifically to a target nucleic acid and specifically to an immobilized probe via binding of members of a specific binding pair in a solution phase of a reaction mixture are disclosed.

The invention provides a single-stranded oligonucleotide (ssON) for use in preventing or treating an influenza virus infection in a subject, wherein the single-stranded oligonucleotide is one that inhibits endocytosis. The invention also provides a single-stranded oligonucleotide (ssON) that comprises or consists of a polynucleotide having a sequence sharing at least 60% sequence identity with a sequence of any one of SEQ ID NOs: 13-21 listed in Table 1, or a complementary sequence thereof.

This invention is in the field of molecular biology, gene expression, functional genomics, and bioinformatics and relates to novel RNA and related structures and methods of use thereof that enables modulation of gene expression and preservation of particular transcriptome targets. The invention contemplates various applications of RNA sequences derived from the genomic RNA of flaviviruses (FVs) and the application of such features in combination with heterologous sequences.

Some embodiments of the methods and compositions provided herein relate to treating a subject suffering from hypertension, a cardiac injury, or a metabolic disorder. Some embodiments include administering an exosome to a subject. Some embodiments include administering an oligonucleotide to the subject. In some embodiments, the oligonucleotide comprises a Y-RNA or Y-RNA fragment such as EV-YF1 or EV-YF1-U16. In some embodiments, the oligonucleotide or exosome also has a therapeutic effect on the subject.